

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 July 2004 (08.07.2004)

PCT

(10) International Publication Number
WO 2004/056782 A1

(51) International Patent Classification⁷: **C07D 231/38**,
405/12, 401/12, 413/12, 403/12, 417/12, 409/12, 403/04,
405/10, 401/04, A61K 31/415 // (C07D 405/12, 307:00,
231:00) (C07D 401/12, 231:00, 213:00)

CB1 6GB (GB). **DYMOCK, Brian, William** [GB/GB];
Vernalis (Cambridge) Limited, Granta Park, Abington,
Cambridge CB1 6GB (GB). **McDONALD, Edward**
[GB/GB]; The Institute of Cancer Research, Royal Cancer
Hospital, 123 Old Brompton Road, London SW7 3RP
(GB).

(21) International Application Number:
PCT/GB2003/005501

(22) International Filing Date:
18 December 2003 (18.12.2003)

(74) Agents: **HOWARD, Paul, Nicholas** et al.; Carpmaels &
Ransford, 43-45 Bloomsbury Square, London WC1A 2RA
(GB).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0229618.4 19 December 2002 (19.12.2002) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,
CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,
SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicants (*for all designated States except US*): **VER-
NALIS (CAMBRIDGE) LIMITED** [GB/GB]; Granta
Park, Abington, Cambridge CB1 6GB (GB). **CANCER
RESEARCH TECHNOLOGY LTD** [GB/GB]; 61
Lincoln's Inn Fields, London WC2A 3PX (GB). **THE
INSTITUTE OF CANCER RESEARCH** [GB/GB];
Royal Cancer Hospital, 123 Old Brompton Road, London
SW7 3RP (GB).

(84) Designated States (*regional*): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **BESWICK,
Mandy, Christine** [GB/GB]; Vernalis (Cambridge)
Limited, Granta Park, Abington, Cambridge CB1 6GB
(GB). **DRYSDALE, Martin, James** [GB/GB]; Vernalis
(Cambridge) Limited, Granta Park, Abington, Cambridge

Published:


— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PYRAZOLE COMPOUNDS



(IA)



(IB)

(57) Abstract: Compounds of formula (IA) or (IB) or a salt, N-oxide, hydrate or solvate thereof are inhibitors of HSP90, and are of value in the treatment of diseases responsive to HSP90 inhibition such as cancers. In the formulae, Ar is an aryl, aryl(C₁-C₆ alkyl), aryl(C₁-C₆ alkyl), heteroaryl, heteroaryl(C₁-C₆ alkyl), or heteroaryl(C₁-C₆ alkyl) group, any of which being optionally substituted in the aryl or heteroaryl part thereof; R₁ is hydrogen or optionally substituted C₁-C₆ alkyl; R₂ is hydrogen, optionally substituted cycloalkyl, cycloalkenyl, C₁-C₆ alkyl, C₁-C₆ alkenyl, or C₁-C₆ alkynyl; or a carboxyl, carboxamide or carboxyl ester group; and ring A is a non aromatic carbocyclic or heterocyclic ring wherein (i) a ring carbon is optionally substituted, and/or (ii) a ring nitrogen is optionally substituted by a group of formula -(Alk¹)_p (Cyc)_n-(Alk³)_m-(Z)_r (Alk²)_s Q where Alk¹, Alk² and Alk³ are optionally substituted C₁-C₃ alkyl, Cyc is an optionally substituted carbocyclic or heterocyclic radical; m, n, p, r and s are independently 0 or 1, Z is -O-, -S-, -(C=O)-, -SO₂-, -C(=O)O-, -OC(=O)-, -NW-, -C(=O)NRA-, -NRA⁺C(=O)-, -SO₂NRA⁺-, or -NRA⁺SO₂- wherein R⁺ is hydrogen or C₁-C₆ alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical.